Adults with Cystic Fibrosis (CF) & Exercise Intolerance
Trial Objectives
.jpg?lang=en-US)
This exercise study is investigating how an already FDA approved drug for treatment of pulmonary vascular disease, sildenafil (Revatio ®), impacts exercise tolerance and capacity in people with cystic fibrosis (CF). Understanding and developing exercise tolerance is important for people with CF. Participants will be randomized to either the study drug group or the placebo group and complete exercise testing.
Who Can Participate
Individuals with moderate to severe CF lung disease.
Age: 18+ Gender: Any
Estimated Time Commitment
16 weeks, five in-person visits, three phone contacts
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
National Jewish Health and Dr. Taylor-Cousar, with Cystic Fibrosis Foundation via Augusta University